A003520 Stock Overview
Operates as a pharmaceutical company in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Yungjin Pharm. Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,120.00 |
| 52 Week High | ₩2,790.00 |
| 52 Week Low | ₩1,950.00 |
| Beta | 0 |
| 11 Month Change | -9.21% |
| 3 Month Change | -14.17% |
| 1 Year Change | -1.40% |
| 33 Year Change | -50.12% |
| 5 Year Change | -67.43% |
| Change since IPO | -96.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| A003520 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 3.2% | -3.1% | 2.9% |
| 1Y | -1.4% | 4.8% | -2.8% |
Return vs Industry: A003520 underperformed the KR Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: A003520 exceeded the KR Market which returned -2.8% over the past year.
Price Volatility
| A003520 volatility | |
|---|---|
| A003520 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A003520 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A003520's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | n/a | Chae-Joon Lee | www.yungjin.co.kr |
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. The company also provides vitamins, minerals, and other products; and APIs.
Yungjin Pharm. Co., Ltd. Fundamentals Summary
| A003520 fundamental statistics | |
|---|---|
| Market cap | ₩382.25b |
| Earnings (TTM) | ₩8.53b |
| Revenue (TTM) | ₩158.79b |
0.0x
P/E Ratio0.0x
P/S RatioIs A003520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A003520 income statement (TTM) | |
|---|---|
| Revenue | ₩158.79b |
| Cost of Revenue | ₩99.50b |
| Gross Profit | ₩59.28b |
| Other Expenses | ₩50.76b |
| Earnings | ₩8.53b |
Last Reported Earnings
Sep 30, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A003520 perform over the long term?
See historical performance and comparison